Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 7INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Myasthenia Gravis 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 82venetoclax 56ibrutinib 46obinutuzumab 43Bendamustine Hydrochloride 40idelalisib 30Cyclophosphamide 29acalabrutinib 28fludarabine 27Chlorambucil 27pirtobrutinib 18ublituximab 16ofatumumab 16zanubrutinib 14umbralisib 14Lenalidomide 11fludarabine phosphate 9Alemtuzumab 9navitoclax 7duvelisib 7Azacitidine 5lumiliximab 4aflibercept 4TRU 016 4Interleukin-2 4BI 836826 4ARQ531 4tafasitamab 3motexafin gadolinium 3dinaciclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Lymphocytic, Chronic, B-Cell × Cladribine × Clear all
NCT00718549 2018-08-20

A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)

Hoffmann-La Roche

Phase 3 Completed
128 enrolled 10 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡